U.S. markets closed
  • S&P Futures

    3,434.75
    +12.00 (+0.35%)
     
  • Dow Futures

    28,187.00
    +87.00 (+0.31%)
     
  • Nasdaq Futures

    11,701.25
    +51.00 (+0.44%)
     
  • Russell 2000 Futures

    1,617.40
    +6.10 (+0.38%)
     
  • Crude Oil

    40.48
    -0.35 (-0.86%)
     
  • Gold

    1,906.20
    -5.50 (-0.29%)
     
  • Silver

    24.61
    -0.08 (-0.34%)
     
  • EUR/USD

    1.1774
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    0.7610
    +0.0170 (+2.28%)
     
  • Vix

    29.18
    +1.77 (+6.46%)
     
  • GBP/USD

    1.2944
    +0.0003 (+0.03%)
     
  • USD/JPY

    105.5430
    +0.1130 (+0.11%)
     
  • BTC-USD

    11,715.72
    +658.71 (+5.96%)
     
  • CMC Crypto 200

    238.62
    +4.95 (+2.12%)
     
  • FTSE 100

    5,884.65
    -34.93 (-0.59%)
     
  • Nikkei 225

    23,596.49
    -74.64 (-0.32%)
     

Novavax Shares Surge 7% As It Begins Late-Stage COVID-19 Vaccine Trials

Shivdeep Dhaliwal
·2 mins read

Novavax, Inc (NASDAQ: NVAX) said Thursday it was launching a large-scale diverse Phase 3 study of its COVID-19 vaccine in the United Kingdom — causing a more than 7% spike in the company’s shares after the closing bell.

What Happened: The study will enroll up to 100,000 individuals, aged between 18-84 years of age, with and without relevant comorbidities, Novavax said in a statement.

The drugmaker said that the trial is being conducted in partnership with the U.K. government’s Vaccines Taskforce and will last over the next four to six weeks.

The Maryland-based drugmaker will enroll at least 25% of participants over the age of 65 to prioritize groups it said were most affected by COVID-19, which includes racial and ethnic minorities.

Why It Matters: Novavax said it has secured $2 billion in funding for its worldwide vaccine program, which includes $388 million from the Coalition for Epidemic Preparedness Innovations, co-founded by the Bill & Melinda Gates Foundation.

Earlier this month, another beneficiary of the Gates Foundation, Pfizer Inc (NYSE: PFE) said participants in its late-stage study only showed mild-to-moderate side effects.

Pfizer and Moderna Inc’s (NASDAQ: MRNA) vaccines may be the first to be distributed in late October or November in the United States, according to the New York Times.

Meanwhile, AstraZeneca plc's (NYSE: AZN) vaccine trials have yet to resume in the U.S., after being halted due to an adverse reaction earlier, leading to scientists questioning the suspension of the trial.

Price Action: Novavax shares rose nearly 7.3% to $109.95 in the after-hours session on Thursday after closing the regular session almost 0.9% higher at $102.44.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.